Alzamend Neuro, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Alzamend Neuro, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2026 | Jan 31, 2026 | ($2.20M) | Mar 11, 2026 |
| Q2 | 2026 | Oct 31, 2025 | ($1.00M) | Dec 9, 2025 |
| Q1 | 2026 | Jul 31, 2025 | ($2.70M) | Sep 10, 2025 |
| Q3 | 2026 | Jan 31, 2025 | ($1.04M) | Mar 11, 2026 |
| Q2 | 2026 | Oct 31, 2024 | ($1.36M) | Dec 9, 2025 |
| Q1 | 2026 | Jul 31, 2024 | ($974.4K) | Sep 10, 2025 |
| Q3 | 2024 | Jan 31, 2024 | ($2.66M) | Mar 10, 2025 |
| Q2 | 2024 | Oct 31, 2023 | ($2.91M) | Dec 11, 2024 |
| Q1 | 2024 | Jul 31, 2023 | ($3.53M) | Sep 11, 2024 |
| Q3 | 2024 | Jan 31, 2023 | ($5.43M) | Mar 25, 2024 |
| Q2 | 2024 | Oct 31, 2022 | ($3.11M) | Dec 15, 2023 |
| Q1 | 2024 | Jul 31, 2022 | ($3.04M) | Sep 13, 2023 |
| Q3 | 2023 | Jan 31, 2022 | ($2.57M) | Mar 15, 2023 |
| Q2 | 2022 | Oct 31, 2021 | ($3.60M) | Dec 12, 2022 |
| Q1 | 2022 | Jul 31, 2021 | ($2.32M) | Sep 13, 2022 |
| Q3 | 2022 | Jan 31, 2021 | ($1.12M) | Mar 15, 2022 |
| Q2 | 2022 | Oct 31, 2020 | ($1.35M) | Dec 13, 2021 |
| Q1 | 2022 | Jul 31, 2020 | ($1.32M) | Sep 13, 2021 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2026 | Jan 31, 2026 | ($2.20M) | Mar 11, 2026 |
| Q2 | 2026 | Oct 31, 2025 | ($998.1K) | Dec 9, 2025 |
| Q1 | 2026 | Jul 31, 2025 | ($2.70M) | Sep 10, 2025 |
| Q3 | 2026 | Jan 31, 2025 | ($1.04M) | Mar 11, 2026 |
| Q2 | 2026 | Oct 31, 2024 | ($1.36M) | Dec 9, 2025 |
| Q1 | 2026 | Jul 31, 2024 | ($962.4K) | Sep 10, 2025 |
| Q3 | 2024 | Jan 31, 2024 | ($2.66M) | Mar 10, 2025 |
| Q2 | 2024 | Oct 31, 2023 | ($2.90M) | Dec 11, 2024 |
| Q1 | 2024 | Jul 31, 2023 | ($3.53M) | Sep 11, 2024 |
| Q3 | 2024 | Jan 31, 2023 | ($5.42M) | Mar 25, 2024 |
| Q2 | 2024 | Oct 31, 2022 | ($3.11M) | Dec 15, 2023 |
| Q1 | 2024 | Jul 31, 2022 | ($3.04M) | Sep 13, 2023 |
| Q3 | 2023 | Jan 31, 2022 | ($2.56M) | Mar 15, 2023 |
| Q2 | 2022 | Oct 31, 2021 | ($3.58M) | Dec 12, 2022 |
| Q1 | 2022 | Jul 31, 2021 | ($2.31M) | Sep 13, 2022 |
| Q3 | 2022 | Jan 31, 2021 | ($1.12M) | Mar 15, 2022 |
| Q2 | 2022 | Oct 31, 2020 | ($1.30M) | Dec 13, 2021 |
| Q1 | 2022 | Jul 31, 2020 | ($1.32M) | Sep 13, 2021 |